NDA Submitted to FDA for Ivosidenib for Previously Treated IDH1-Mutated Cholangiocarcinoma

A supplemental new drug application has been submitted to the FDA for ivosidenib tablets (Tibsovo) as a potential therapeutic option for patients with previously treated, IDH1-mutated cholangiocarcinoma.

Related Keywords

Chris Bowden , ,Specialty Pharmacy ,Oncology ,Hospital ,News ,கிறிஸ் போடன் ,சிறப்பு மருந்தகம் ,புற்றுநோயியல் ,மருத்துவமனை ,செய்தி ,